Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes

The probability of progression from “preclinical” diabetic retinopathy to proliferative retinopathy or clinical macular edema was estimated. Individualized screening frequency based on the current retinopathy state and glycated hemoglobin level appeared to be feasible. Diabetic retinopathy is the mo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2017-04, Vol.376 (16), p.1507-1516
Hauptverfasser: Nathan, David M, Bebu, Ionut, Hainsworth, Dean, Klein, Ronald, Tamborlane, William, Lorenzi, Gayle, Gubitosi-Klug, Rose, Lachin, John M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1516
container_issue 16
container_start_page 1507
container_title The New England journal of medicine
container_volume 376
creator Nathan, David M
Bebu, Ionut
Hainsworth, Dean
Klein, Ronald
Tamborlane, William
Lorenzi, Gayle
Gubitosi-Klug, Rose
Lachin, John M
description The probability of progression from “preclinical” diabetic retinopathy to proliferative retinopathy or clinical macular edema was estimated. Individualized screening frequency based on the current retinopathy state and glycated hemoglobin level appeared to be feasible. Diabetic retinopathy is the most common cause of blindness in adults in the United States. 1 Fortunately, the risk of the development and progression of retinopathy can be reduced substantially by modern-day intensive glycemic management. 2 – 5 Moreover, if clinically significant macular edema or vision-threatening proliferative diabetic retinopathy develops, timely intervention with laser photocoagulation or with intraocular glucocorticoids or anti–vascular endothelial growth factor (VEGF) agents can substantially reduce loss of vision. 6 – 9 Thus, the goal of retinopathy screening is the timely detection of retinopathy that would, without intervention, cause vision loss. In patients with type 1 diabetes, annual screening for retinopathy starting . . .
doi_str_mv 10.1056/NEJMoa1612836
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5557280</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4321886129</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-2f30b4b2f92058bf7c49dfe2c899cab3810c8f76c4a024f073d0ab03406c7b5d3</originalsourceid><addsrcrecordid>eNp1kd9rFDEQx4Mo9lp99FUCIvRldfJrN_si1Hq1SlXQ-hyy2Umb4zY5k73C_femXC1WcGCYgfnwZb58CXnB4A0D1b79uvz8JVnWMq5F-4gsmBKikRLax2QBwHUju14ckMNSVlCLyf4pOeBaciFALcj5WcZfW4xuR5Ony5sw1h2b97bgSH-4jBhDvKI-Zfod5xDTxs7XOxoivdxtkDL6IdgBZyzPyBNv1wWf380j8vNseXl63lx8-_jp9OSicVKqueFewCAH7nsOSg--c7IfPXKn-97ZQWgGTvuuddIClx46MYIdQFRDrhvUKI7Iu73uZjtMODqMc7Zrs8lhsnlnkg3m4SWGa3OVboxSquMaqsDxnUBO1XmZzRSKw_XaRkzbYpjuGdRuRUVf_YOu0jbHau-WAi6k6lSlmj3lciolo79_hoG5zcg8yKjyL_92cE__CaUCr_fANBUTcTX9R-g3st6XaA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1890234575</pqid></control><display><type>article</type><title>Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>New England Journal of Medicine</source><creator>Nathan, David M ; Bebu, Ionut ; Hainsworth, Dean ; Klein, Ronald ; Tamborlane, William ; Lorenzi, Gayle ; Gubitosi-Klug, Rose ; Lachin, John M</creator><creatorcontrib>Nathan, David M ; Bebu, Ionut ; Hainsworth, Dean ; Klein, Ronald ; Tamborlane, William ; Lorenzi, Gayle ; Gubitosi-Klug, Rose ; Lachin, John M ; The DCCT/EDIC Research Group ; DCCT/EDIC Research Group</creatorcontrib><description>The probability of progression from “preclinical” diabetic retinopathy to proliferative retinopathy or clinical macular edema was estimated. Individualized screening frequency based on the current retinopathy state and glycated hemoglobin level appeared to be feasible. Diabetic retinopathy is the most common cause of blindness in adults in the United States. 1 Fortunately, the risk of the development and progression of retinopathy can be reduced substantially by modern-day intensive glycemic management. 2 – 5 Moreover, if clinically significant macular edema or vision-threatening proliferative diabetic retinopathy develops, timely intervention with laser photocoagulation or with intraocular glucocorticoids or anti–vascular endothelial growth factor (VEGF) agents can substantially reduce loss of vision. 6 – 9 Thus, the goal of retinopathy screening is the timely detection of retinopathy that would, without intervention, cause vision loss. In patients with type 1 diabetes, annual screening for retinopathy starting . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1612836</identifier><identifier>PMID: 28423305</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adolescent ; Adult ; Clinical significance ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (insulin dependent) ; Diabetes Mellitus, Type 1 - complications ; Diabetic retinopathy ; Diabetic Retinopathy - diagnosis ; Disease Progression ; Edema ; Epidemiology ; Evidence-Based Medicine ; Eye examinations ; Follow-Up Studies ; Glycated Hemoglobin - analysis ; Hemoglobin ; Humans ; Intervention ; Macular Edema - diagnosis ; Markov Chains ; Medical screening ; Photography ; Practice Guidelines as Topic ; Retina ; Retina - pathology ; Retinopathy ; Risk Factors ; Schedules ; Vascular endothelial growth factor ; Visual Acuity ; Young Adult</subject><ispartof>The New England journal of medicine, 2017-04, Vol.376 (16), p.1507-1516</ispartof><rights>Copyright © 2017 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-2f30b4b2f92058bf7c49dfe2c899cab3810c8f76c4a024f073d0ab03406c7b5d3</citedby><cites>FETCH-LOGICAL-c445t-2f30b4b2f92058bf7c49dfe2c899cab3810c8f76c4a024f073d0ab03406c7b5d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1612836$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1612836$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,776,780,881,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28423305$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nathan, David M</creatorcontrib><creatorcontrib>Bebu, Ionut</creatorcontrib><creatorcontrib>Hainsworth, Dean</creatorcontrib><creatorcontrib>Klein, Ronald</creatorcontrib><creatorcontrib>Tamborlane, William</creatorcontrib><creatorcontrib>Lorenzi, Gayle</creatorcontrib><creatorcontrib>Gubitosi-Klug, Rose</creatorcontrib><creatorcontrib>Lachin, John M</creatorcontrib><creatorcontrib>The DCCT/EDIC Research Group</creatorcontrib><creatorcontrib>DCCT/EDIC Research Group</creatorcontrib><title>Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>The probability of progression from “preclinical” diabetic retinopathy to proliferative retinopathy or clinical macular edema was estimated. Individualized screening frequency based on the current retinopathy state and glycated hemoglobin level appeared to be feasible. Diabetic retinopathy is the most common cause of blindness in adults in the United States. 1 Fortunately, the risk of the development and progression of retinopathy can be reduced substantially by modern-day intensive glycemic management. 2 – 5 Moreover, if clinically significant macular edema or vision-threatening proliferative diabetic retinopathy develops, timely intervention with laser photocoagulation or with intraocular glucocorticoids or anti–vascular endothelial growth factor (VEGF) agents can substantially reduce loss of vision. 6 – 9 Thus, the goal of retinopathy screening is the timely detection of retinopathy that would, without intervention, cause vision loss. In patients with type 1 diabetes, annual screening for retinopathy starting . . .</description><subject>Adolescent</subject><subject>Adult</subject><subject>Clinical significance</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Diabetes Mellitus, Type 1 - complications</subject><subject>Diabetic retinopathy</subject><subject>Diabetic Retinopathy - diagnosis</subject><subject>Disease Progression</subject><subject>Edema</subject><subject>Epidemiology</subject><subject>Evidence-Based Medicine</subject><subject>Eye examinations</subject><subject>Follow-Up Studies</subject><subject>Glycated Hemoglobin - analysis</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Intervention</subject><subject>Macular Edema - diagnosis</subject><subject>Markov Chains</subject><subject>Medical screening</subject><subject>Photography</subject><subject>Practice Guidelines as Topic</subject><subject>Retina</subject><subject>Retina - pathology</subject><subject>Retinopathy</subject><subject>Risk Factors</subject><subject>Schedules</subject><subject>Vascular endothelial growth factor</subject><subject>Visual Acuity</subject><subject>Young Adult</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kd9rFDEQx4Mo9lp99FUCIvRldfJrN_si1Hq1SlXQ-hyy2Umb4zY5k73C_femXC1WcGCYgfnwZb58CXnB4A0D1b79uvz8JVnWMq5F-4gsmBKikRLax2QBwHUju14ckMNSVlCLyf4pOeBaciFALcj5WcZfW4xuR5Ony5sw1h2b97bgSH-4jBhDvKI-Zfod5xDTxs7XOxoivdxtkDL6IdgBZyzPyBNv1wWf380j8vNseXl63lx8-_jp9OSicVKqueFewCAH7nsOSg--c7IfPXKn-97ZQWgGTvuuddIClx46MYIdQFRDrhvUKI7Iu73uZjtMODqMc7Zrs8lhsnlnkg3m4SWGa3OVboxSquMaqsDxnUBO1XmZzRSKw_XaRkzbYpjuGdRuRUVf_YOu0jbHau-WAi6k6lSlmj3lciolo79_hoG5zcg8yKjyL_92cE__CaUCr_fANBUTcTX9R-g3st6XaA</recordid><startdate>20170420</startdate><enddate>20170420</enddate><creator>Nathan, David M</creator><creator>Bebu, Ionut</creator><creator>Hainsworth, Dean</creator><creator>Klein, Ronald</creator><creator>Tamborlane, William</creator><creator>Lorenzi, Gayle</creator><creator>Gubitosi-Klug, Rose</creator><creator>Lachin, John M</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170420</creationdate><title>Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes</title><author>Nathan, David M ; Bebu, Ionut ; Hainsworth, Dean ; Klein, Ronald ; Tamborlane, William ; Lorenzi, Gayle ; Gubitosi-Klug, Rose ; Lachin, John M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-2f30b4b2f92058bf7c49dfe2c899cab3810c8f76c4a024f073d0ab03406c7b5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Clinical significance</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Diabetes Mellitus, Type 1 - complications</topic><topic>Diabetic retinopathy</topic><topic>Diabetic Retinopathy - diagnosis</topic><topic>Disease Progression</topic><topic>Edema</topic><topic>Epidemiology</topic><topic>Evidence-Based Medicine</topic><topic>Eye examinations</topic><topic>Follow-Up Studies</topic><topic>Glycated Hemoglobin - analysis</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Intervention</topic><topic>Macular Edema - diagnosis</topic><topic>Markov Chains</topic><topic>Medical screening</topic><topic>Photography</topic><topic>Practice Guidelines as Topic</topic><topic>Retina</topic><topic>Retina - pathology</topic><topic>Retinopathy</topic><topic>Risk Factors</topic><topic>Schedules</topic><topic>Vascular endothelial growth factor</topic><topic>Visual Acuity</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nathan, David M</creatorcontrib><creatorcontrib>Bebu, Ionut</creatorcontrib><creatorcontrib>Hainsworth, Dean</creatorcontrib><creatorcontrib>Klein, Ronald</creatorcontrib><creatorcontrib>Tamborlane, William</creatorcontrib><creatorcontrib>Lorenzi, Gayle</creatorcontrib><creatorcontrib>Gubitosi-Klug, Rose</creatorcontrib><creatorcontrib>Lachin, John M</creatorcontrib><creatorcontrib>The DCCT/EDIC Research Group</creatorcontrib><creatorcontrib>DCCT/EDIC Research Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nathan, David M</au><au>Bebu, Ionut</au><au>Hainsworth, Dean</au><au>Klein, Ronald</au><au>Tamborlane, William</au><au>Lorenzi, Gayle</au><au>Gubitosi-Klug, Rose</au><au>Lachin, John M</au><aucorp>The DCCT/EDIC Research Group</aucorp><aucorp>DCCT/EDIC Research Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2017-04-20</date><risdate>2017</risdate><volume>376</volume><issue>16</issue><spage>1507</spage><epage>1516</epage><pages>1507-1516</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>The probability of progression from “preclinical” diabetic retinopathy to proliferative retinopathy or clinical macular edema was estimated. Individualized screening frequency based on the current retinopathy state and glycated hemoglobin level appeared to be feasible. Diabetic retinopathy is the most common cause of blindness in adults in the United States. 1 Fortunately, the risk of the development and progression of retinopathy can be reduced substantially by modern-day intensive glycemic management. 2 – 5 Moreover, if clinically significant macular edema or vision-threatening proliferative diabetic retinopathy develops, timely intervention with laser photocoagulation or with intraocular glucocorticoids or anti–vascular endothelial growth factor (VEGF) agents can substantially reduce loss of vision. 6 – 9 Thus, the goal of retinopathy screening is the timely detection of retinopathy that would, without intervention, cause vision loss. In patients with type 1 diabetes, annual screening for retinopathy starting . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>28423305</pmid><doi>10.1056/NEJMoa1612836</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-4793
ispartof The New England journal of medicine, 2017-04, Vol.376 (16), p.1507-1516
issn 0028-4793
1533-4406
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5557280
source MEDLINE; EZB-FREE-00999 freely available EZB journals; New England Journal of Medicine
subjects Adolescent
Adult
Clinical significance
Diabetes
Diabetes mellitus
Diabetes mellitus (insulin dependent)
Diabetes Mellitus, Type 1 - complications
Diabetic retinopathy
Diabetic Retinopathy - diagnosis
Disease Progression
Edema
Epidemiology
Evidence-Based Medicine
Eye examinations
Follow-Up Studies
Glycated Hemoglobin - analysis
Hemoglobin
Humans
Intervention
Macular Edema - diagnosis
Markov Chains
Medical screening
Photography
Practice Guidelines as Topic
Retina
Retina - pathology
Retinopathy
Risk Factors
Schedules
Vascular endothelial growth factor
Visual Acuity
Young Adult
title Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A53%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Frequency%20of%20Evidence-Based%20Screening%20for%20Retinopathy%20in%20Type%201%20Diabetes&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Nathan,%20David%20M&rft.aucorp=The%20DCCT/EDIC%20Research%20Group&rft.date=2017-04-20&rft.volume=376&rft.issue=16&rft.spage=1507&rft.epage=1516&rft.pages=1507-1516&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa1612836&rft_dat=%3Cproquest_pubme%3E4321886129%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1890234575&rft_id=info:pmid/28423305&rfr_iscdi=true